LG Chem's novel cancer drug candidate targeting rare mutation gains FDA approval for clinical trials

LG Chem is advancing into uncharted territory in cancer treatment with its new drug candidate, LG00313112. The U.S. Food and Drug Administration (FDA) has greenlit the company's plan for Phase 1/2 clinical trials, marking a significant step for a therapy targeting the rare TP53 Y220C mutation.

This specific mutation, found in 1-3% of cancer patients, disrupts the normal function of the p53 protein, a crucial guardian of the genome that normally triggers cell death in response to DNA damage. The TP53 Y220C mutation alters the protein's structure, leading to cancer. Patients with this mutation have a significantly shorter survival rate compared to those without it, and currently, no approved treatments exist.

“

We will increase the success rate of new drug development by efficiently selecting patients who are expected to respond to treatment through a clear biomarker-based precision medicine approach.

LG Chem's candidate drug works by stabilizing the structurally compromised p53 protein, aiming to restore its tumor-suppressing capabilities. The company highlights its novel covalent drug design, which is expected to provide stable target binding and sustained efficacy. Preclinical studies have shown promising anti-cancer effects and sustained drug response even at low doses.

To expedite the development process, LG Chem has designed an integrated Phase 1/2 clinical trial. This approach will allow for the early acquisition of dosing and efficacy data, shortening the overall development timeline. The initial phase will focus on evaluating safety, tolerability, and preliminary efficacy in patients with advanced solid tumors, including ovarian, lung, and breast cancers, that possess the TP53 Y220C mutation.

“

We will accelerate the speed of new drug development so that cancer patients with limited treatment options can live healthier lives for longer.